For Immediate Release
Chicago, IL – December 6, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: uniQure N.V. (
QURE Quick Quote QURE - Free Report) , Sarepta Therapeutics, Inc. SRPT, BioMarin Pharmaceutical Inc. BMRN and Sangamo Therapeutics, Inc. SGMO. Here are highlights from Thursday’s Analyst Blog: 4 Solid Gene Therapy Buyout Bets
The ongoing M&A wave in the pharma/biotech sector gains further momentum from the significant rally in the share price movement of gene therapy company Audentes Therapeutics, Inc. earlier in the week. The stock’s impressive upsurge followed the Japanese company Astellas Pharma Inc’s announcement to acquire Audentes for a cash consideration of $60 per share or a total deal value of approximately $3 billion. The offer price represents a premium of 110% to Audentes’ closing share price of $28.61 on Dec 2, 2019.
It is interesting to note that attractive modest valuations on account of a disappointing run in 2018 rekindled interest in the ever-volatile biotech sector from the start of this year. Evidently, the spotlight is back on mergers & acquisitions. A slowdown in mature products due to increasing competition and the rise of biosimilars forced most pharma behemoths to target lucrative buyouts in the biotech space to bolster their pipelines. While oncology and immuno-oncology are the key areas of focus, companies targeting non-alcoholic steatohepatitis (NASH), rare diseases and candidates based on gene therapy also promise great potential, thereby making the respective areas profitable for investments.
Bristol-Myers Squibb Company, one of the largest pharma giants, acquired leading biotech company Celgene for a whopping $74 billion in what could be a major acquisition of recent times. Thereafter, a slew of deals was struck with most companies eyeing smaller entities with impressive pipelines, the latest being the Swiss pharma leader Novartis, which reached an agreement to acquire U.S.-based biopharmaceutical company, The Medicines Company, for $9.7 billion.
Earlier in the year, Roche announced that it will acquire gene therapy company Spark Therapeutics Inc. However, the buyout has been getting delayed, dampening hopes of investors.
Nevertheless, the recent acquisition announcement by Astellas brings the gene therapy space into prominence once again.
What is Gene Therapy?
Gene therapy enables to mitigate the adverse effects of a malfunctioning disease-causing gene. The therapy intends to add a functional gene to a person's system, replacing the malfunctioning one to cure diseases. The gene is delivered to a cell though a carrier known as vector. The therapy has a different approach from the traditional drug treatments as the underlying cause can be treated with it.
Gene therapy is set to become one of the most vital spaces with high prospects in the volatile biotech sector. The promising therapy is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, cancer among others.
Gene Therapy Companies in Focus
Given the potential of the therapy to treat complex diseases, the companies developing candidates using gene therapy are in focus. Let us consider a few players with promising drugs/candidates in their portfolios/pipelines as they appear attractive targets of acquisition:
uniQure N.V. is one of the most promising players in this space with a focused pipeline of innovative gene therapies for hemophilia B and Huntington’s disease. Etranacogene dezaparvovec is its lead gene therapy candidate and includes an AAV5 vector incorporating the Factor IX-Padua variant. The company is currently conducting a pivotal study in patients with severe and moderately-severe hemophilia B. The candidate is granted a Breakthrough Therapy Designation by the FDA. In early September 2019, the company completed patient enrollment in its HOPE-B pivotal study of etranacogene dezaparvovec for the treatment of patients with severe and moderately severe hemophilia B. uniQure expects to provide top-line Factor IX (FIX) activity data on all patients before the end of 2020 and submit a Biologics License Application (BLA) for the marketing authorization of etranacogene dezaparvovec in 2021.
With a market cap of $2.85 billion, this company is the front runner for a likely buyout. uniQure currently carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Commercial-stage biopharmaceutical company
Sarepta Therapeutics, Inc. is focused on developing unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Its first commercial product Exondys 51 is indicated to address DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Sarepta is also developing gene therapies for treating Limb-girdle muscular dystrophy (LGMD) and central nervous system disorders including Mucopolysaccharidosis type IIIA (MPS IIIA) and Pompe Disease.
With a market cap of $8.3 billion, Sarepta has been on the radar for quite some time now.
BioMarin Pharmaceutical Inc. develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. With a market cap of $14.6 billion, the company boasts an excellent portfolio of seven commercialized products and an impressive pipeline. It recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A. BioMarin is on track to submit a BLA to the FDA by this year-end. The FDA granted valoctocogene roxaparvovec a Breakthrough Therapy designation. Valoctocogene roxaparvovec received an Orphan Drug tag from the FDA and the EMA. Sangamo Therapeutics, Inc. continues to advance its SB-525 hemophilia A gene therapy program. It is conducting a phase I/II Alta study, an open-label, ascending-dose clinical study to evaluate investigational SB-525 gene therapy for severe hemophilia A in collaboration with Pfizer IncThe FDA conferred a regenerative medicine advanced therapy or RMAT status on SB-525 gene therapy to treat severe hemophilia. This includes all the benefits of the fast track and breakthrough therapy designation programs including early interactions with the FDA. Sangamo is also evaluating its wholly-owned investigational ST-920 gene therapy for Fabry disease, an inherited metabolic disease. The FDA also granted Orphan Drug Designation to ST-920 for the treatment of Fabry disease. The company has a market cap of $1.36 billion. More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.